CN114468046A - Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach - Google Patents

Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach Download PDF

Info

Publication number
CN114468046A
CN114468046A CN202011266653.6A CN202011266653A CN114468046A CN 114468046 A CN114468046 A CN 114468046A CN 202011266653 A CN202011266653 A CN 202011266653A CN 114468046 A CN114468046 A CN 114468046A
Authority
CN
China
Prior art keywords
composition
product
protecting
alcohol
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011266653.6A
Other languages
Chinese (zh)
Inventor
文良柱
方宏清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Wanbang Pharmaceutical Technology Co ltd
Original Assignee
Jiangsu Wanbang Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Wanbang Pharmaceutical Technology Co ltd filed Critical Jiangsu Wanbang Pharmaceutical Technology Co ltd
Priority to CN202011266653.6A priority Critical patent/CN114468046A/en
Publication of CN114468046A publication Critical patent/CN114468046A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/18—Milk in dried and compressed or semi-solid form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/385—Concentrates of non-alcoholic beverages
    • A23L2/39—Dry compositions
    • A23L2/395—Dry compositions in a particular shape or form
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/113—Acidophilus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/123—Bulgaricus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/175—Rhamnosus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/531—Lactis

Abstract

The invention discloses a composition with effects of relieving alcoholism, protecting liver and protecting stomach. The product prepared from the composition has effects of promoting alcohol metabolism, improving intestinal microbial flora balance, relieving hangover, protecting liver and protecting stomach.

Description

Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach
Technical Field
The invention relates to a composition containing oligopeptide and probiotics as effective ingredients and having the effects of relieving alcohol damage and protecting gastrointestinal mucosa and a product containing the composition.
Background
With the development of economy and the increase of social activities, drinking has become a life habit spread all over the world. The pleasure brought by proper drinking can relieve tension, and is beneficial to social contact and friendship. Excessive drinking can cause nausea, vomiting, thirst, headache and myalgia, and affect daily life. In recent years, the global alcohol consumption is on the rise, and more alcoholic liver patients are at home and abroad. According to statistics, 80% of alcoholics show a certain degree of alcoholic liver injury characteristics, wherein 10% -35% can develop into alcoholic hepatitis, and 10% -20% can develop into alcoholic cirrhosis. WHO reports that 2016 alcohol caused about 300 million deaths, accounting for 5.3% of all deaths worldwide.
Acute or chronic alcohol consumption can affect gastric function. The alcoholics have high incidence rate of gastric mucosa atrophy and low gastric secretion ability. The reduction of gastric acid secretion weakens the killing power to pathogenic bacteria, and more harmful bacteria enter the small intestine to settle. Animal and human experiment research shows that alcohol with concentration over 10% can damage gastric mucosa and increase permeability of the mucosa. Changes in short term exposure to alcohol are rapidly reversible. But long term exposure can interfere with microcirculation, leading to progressive mucosal structural damage. (Bode C and Bode JC. Alcohol's Role in gastroenterological train disorders. Alcohol Health & Research World,1997,21: 76-83).
Excessive alcohol consumption often causes damage to the mucosa of the anterior duodenum. The normal person may also cause duodenal erosion and hemorrhage after drinking too much once. Ethanol destroys the integrity of the mucosal epithelium and induces the release of harmful signaling molecules such as cytokines, histamine and leukotrienes. These molecules damage the small vessel walls or capillaries in the small intestinal mucosa, induce blood coagulation, and tear villi, resulting in the entry of some macromolecules, such as bacterial toxins like endotoxin, into blood vessels and lymph. Animal experiment research shows that ethanol increases the permeability of small intestinal mucosa, and some macromolecules can enter blood by taking the opportunity. Endotoxins and other bacterial toxins enter the blood and subsequently reach the liver. Endotoxin can be detected in early-stage alcoholic liver injury patients. The content of endotoxin-producing bacteria in the jejunum of alcoholics is higher than that of normal persons, and more endotoxin enters the blood and reaches the Liver to aggravate Liver injury in addition to the increase of mucosal permeability (Rao RK, et al. recent Advances in alcoholic Liver Disease I.role of endogenous lipid and endoxemia in alcoholic Liver Disease. American Journal of physiological tissue Physiology,2004,286: G881-884).
After absorption in the body, alcohol is metabolized mainly in the liver, and the metabolic products are mainly acetaldehyde and acetic acid. Among the enzymes involved in Alcohol metabolism are Alcohol Dehydrogenase (ADH) and Aldehyde dehydrogenase (ALDH). Firstly, converting alcohol into acetaldehyde under the catalysis of ADH; acetaldehyde is then converted to acetic acid under ALDH catalysis. Acetaldehyde is toxic and causes various symptoms such as fatigue, sleep disorder, palpitation, trembling, and vomiting. Acetaldehyde, the most likely to cause liver damage, acts as a major toxic substance and prevents mitochondrial oxidation and thus the increase in this toxic substance. Acetaldehyde can bind to various proteins in the liver to form adducts of acetaldehyde protein, changing the protein surface charge conformation, resulting in denaturation of functional proteins and even exposing some surface antigens, thereby stimulating the body to produce antibodies to elicit an autoimmune response, resulting in liver damage (Tuma DJ, Casey CA. Dangerous bypass of alcohol Research & Health,2003,27: 285-. Alcohol that is not metabolized in time is transferred to the brain along the blood to stimulate the central nervous system, thereby affecting the function of the brain, resulting in decreased judgment ability.
Furthermore, Alcohol also affects the Intestinal microbial balance (Engen PA, et al. the Gastrointestinal Microbiome-Alcohol Effects on the Composition of interest Microbiol. Alcohol Research: Current Reviews,2015,37: 223-. Alcohol enters the small intestine through the stomach and is absorbed by the small intestine by approximately 80%, but the absorption rate of the small intestine is slow. The existence of long-term high-concentration alcohol in the intestinal tract can cause the imbalance of normal flora in the intestinal tract, the reduction of the quantity of intestinal probiotics and the overgrowth of pathogenic bacteria such as gram-negative bacteria and the like, thereby causing the increase of endotoxin in the intestinal tract contents; moreover, excessive alcohol in the intestinal tract and unbalanced intestinal flora can also cause the permeability of the intestinal tract to be increased, so that endotoxin in intestinal contents enters blood, the endotoxin in the blood is increased, and the liver injury is caused.
The gut microbiome contains 100 trillion, at least 2000 different microorganisms, most of which belong to the phylum Firmicutes and Bacteroidetes. The intestinal microbiome contains more than 300 ten thousand unique genes, which is 150 times of the human gene. There is a symbiotic relationship between gastrointestinal and intestinal microorganisms. Microorganisms help to take energy from food, synthesize vitamins and amino acids, and help to establish a barrier against pathogenic bacteria. Disruption of the intestinal microbial homeostasis, associated with Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), celiac disease (celiac disease), food allergy, type I diabetes, type II diabetes, cancer, obesity, and cardiovascular disease, among others.
The alcohol lavage can cause bacterial overgrowth in the small intestine of the mice and ecological imbalance in the caecum. The number of firmicutes decreased and the number of bacteroidetes and verrucomicrobia increased. Long-term drinking results in changes in the microbiome in humans, a decrease in the number of bacteroidetes, an increase in the number of proteobacteria and clostridia (gram-negative bacteria), and an increase in the endotoxin content of the blood. The results of the colon microbiome comparison study of 48 alcoholics and 18 healthy people showed that the number of bacteroidetes in the intestinal tract of the micro-ecologically disordered alcoholics decreased and the number of proteobacteria increased compared to the normal population. This change is closely related to the rise of endotoxin levels in serum. This trend of change still exists even after a period of wine abstinence (Mutlu EA, et al. colloid microbiome analyzed in alcohol. am. J. Physiol Gastrointest Liver physical, 2012,302: G966-G978).
In conclusion, drinking alcohol, especially excessive drinking alcohol, not only has great harm to the gastrointestinal tract, liver and brain, but also destroys the ecological balance of intestinal microorganisms, and the influence lasts for a long time. There is an urgent need for a product that can accelerate alcohol metabolism, reduce the harm to human body, protect gastrointestinal mucosa, and restore intestinal microbial balance.
Disclosure of Invention
The invention provides a composition for reducing the harm of drinking to organisms and protecting gastrointestinal tract and liver and a product containing the composition.
The application provides a composition with effects of relieving alcoholism, protecting liver and protecting stomach, wherein each 5g of the composition comprises 1000-5000 mg of corn oligopeptide powder, 50-400 mg of wheat oligopeptide powder and 1 x 10 of probiotics10～10×1010Colony Forming Units (CFU).
The probiotics comprise lactobacillus acidophilus LA-10A (with the preservation number of CCTCC NO: M2019012), lactobacillus acidophilus NCFM (sold in the market), lactobacillus bulgaricus NJ441 (with the preservation number of CCTCC NO: M2014249), lactobacillus rhamnosus NJ551(CCTCC NO: M2016157) and bifidobacterium lactis NJ 241. The probiotics can be mixed in any proportion, can be mixed by market purchase, and can also be directly purchased as mixed products, such as probiotics or composite probiotic powder of Shanken biotechnology (Suzhou) limited company.
The corn oligopeptide can be purchased from the market and approved by the national health and family planning committee of the people's republic of China in 2010 to be used as a new resource food for starting use.
The wheat oligopeptide can be purchased from the market and approved as a new resource food by the national health and family planning committee of the people's republic of China in 2012.
In certain embodiments, 3000-5000 mg, preferably 3500-4500 mg, more preferably 4000mg of corn oligopeptide flour is included per 5g of the composition.
In certain embodiments, the wheat oligopeptide flour is 100-300 mg, preferably 150-250 mg, more preferably 200mg per 5g of the composition.
In certain embodiments, every 5g groupThe composition contains 2 × 10 probiotics10～10×1010CFU, preferably 5X 1010～10×1010CFU, more preferably 5X 1010CFU。
In certain embodiments, each of the smallest packaged products comprises:
3000-5000 mg, for example 4000mg, of corn oligopeptide powder;
150-250 mg, for example 200mg, of wheat oligopeptide powder;
mixed probiotics, 2X 1010～10×1010CFU, e.g. 5X 1010And (4) CFU. Contains Lactobacillus acidophilus LA-10A, Lactobacillus acidophilus NCFM, Lactobacillus bulgaricus NJ441, Lactobacillus rhamnosus NJ551 and Bifidobacterium lactis NJ 241.
The invention also provides a product, and the product or the raw material of the product comprises the composition with the effects of relieving alcoholism, protecting liver and protecting stomach.
The product according to the invention is typically a food product, such as a general food product or a health food product, such as a yoghurt, a lactic acid bacteria drink, a milk tablet, a solid drink or a tabletted candy.
The products of the invention may be prepared according to methods conventional in the art, such as by mixing, granulating or tableting the ingredients comprising the composition.
The invention also provides a method for preparing the composition for relieving alcoholism, protecting liver and protecting stomach, and the composition with the efficacies of relieving alcoholism, protecting liver and protecting stomach is administered.
The invention also provides application of the composition with the effects of relieving alcoholism, protecting liver and protecting stomach in preparation of products.
The product according to the invention is typically a food product, such as a general food product or a health food product, such as a yoghurt, a lactic acid bacteria drink, a milk tablet, a solid drink or a tabletted candy.
The invention also provides application of the composition for relieving alcoholism, protecting liver and protecting stomach or the product in preparation of products for preventing and/or assisting in treatment of chemical liver injury (such as alcoholic liver injury).
Advantageous effects
The composition or product of the invention can improve the discomfort after drinking, shorten the drunk time and/or sober-up time of drinkers, reduce the blood ethanol content of drinkers and/or reduce the ethanol accumulation in the blood of drinkers. The composition or product of the present invention can be taken before drinking to prevent drunkenness. In addition, the composition or the product of the invention has auxiliary protection effect on alcoholic liver injury.
Drawings
FIG. 1 measurement of ethanol concentration in serum after acute alcohol drinking.
FIG. 2 ADH and ALDH activity assay in stomach tissue after acute alcohol consumption.
FIG. 3 measurement of TNF-alpha content in stomach tissue after acute drinking.
FIG. 4 determination of GSH, MDA and TG content in liver tissue after acute drinking.
FIG. 5.Hp infection in mice, serum IL-6 levels and ADH activity in stomach tissue.
FIG. 6. Effect of oligopeptide powder probiotic composition on intestinal microbiome content of mice drunk for a long period of time.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to the drawings and examples, but those skilled in the art will understand that the following drawings and examples are only for illustrating the present invention and are not to be construed as limiting the scope of the present invention. Various objects and advantageous aspects of the present invention will be readily apparent to those skilled in the art from the drawings and the detailed description of the preferred embodiments.
The "oligopeptide powder probiotic composition" in the examples, each minimum package (5g) containing: 4g of corn oligopeptide powder, 0.2g of wheat oligopeptide powder and 500 hundred million probiotics.
The "protein powder probiotic composition" in the examples, each minimum package (5g) contains: 4.2g of commercial protein powder and 500 hundred million of probiotics.
"oligopeptide powder" in the examples, each minimum package (4.2g) containing: 4g of corn oligopeptide powder and 0.2g of wheat oligopeptide powder.
The main raw materials are as follows:
corn oligopeptide powder: zhongshidu Qing (Shandong) Biotech limited.
Wheat oligopeptide powder: zhongshidu Qing (Shandong) Biotech Co., Ltd.
Mixing probiotic powder: shanenkang Biotechnology, Inc. (Suzhou), contains Lactobacillus acidophilus LA-10A, Lactobacillus acidophilus NCFM, Lactobacillus bulgaricus NJ441, Lactobacillus rhamnosus NJ551, and Bifidobacterium lactis NJ 241.
Commercial protein powder: the vegetable protein powder is used as a tonic.
Example 1 protective Effect of oligopeptide probiotic composition on acute alcoholism mice
40 Kunming mice (6 weeks old, male, weight range 20 +/-2 g, Nanjing Junke Biotechnology Co., Ltd.) were adaptively bred for one week, and randomly divided into 4 groups, namely a normal control group, a model control group, a protein powder probiotic composition group (protein powder group), and an oligopeptide powder probiotic composition group (oligopeptide group), wherein each group contains 10 mice. Mice of each group were labeled, weighed and recorded prior to the experiment. From the second week, performing intragastric administration at 9 am every day, wherein the intragastric administration volume is 0.4mL each, continuously performing intragastric administration for 10 days, and the normal group and the model group are infused with physiological saline with the same volume, wherein the protein powder group contains 65mg of protein powder probiotic composition, and the oligopeptide powder group contains 65mg of oligopeptide powder probiotic composition (converted according to 5 times of human body dose).
And after the intragastric administration of each group is finished on the 10 th day, fasting is carried out for 12h, intragastric administration is continued on the 11 th day according to the method, and after 30min, except for the normal group, mice of other groups are intragastric administered with 56-degree Hongxing Erguotou liquor in a volume of 0.28mL/20g of body weight.
After the mice are subjected to intragastric administration for 1h, the eyeballs are picked and blood is taken, serum is obtained, and the concentration of ethanol in the serum is measured.
Mice were sacrificed by cervical dislocation and the stomach was removed by laparotomy. The stomach tissue was rinsed with normal saline, blotted dry with filter paper, weighed and recorded, and a stomach homogenate was prepared and the Alcohol Dehydrogenase (ADH) activity, acetaldehyde dehydrogenase (ALDH) activity and TNF-. alpha.content in the stomach tissue were measured.
A part of the liver of a mouse is taken and placed in physiological saline to prepare 10% liver homogenate, and reduced Glutathione (GSH), Malondialdehyde (MDA) and Triglyceride (TG) detection is carried out.
The concentration of ethanol in serum is determined by using a blood ethanol test box (Nanjing institute of bioengineering) according to the instruction.
ADH activity in stomach tissue was determined using ADH kit (Nanjing institute of bioengineering) according to the instructions. The ADH activity is obtained by measuring the change rate of absorbance at 340nm in mouse stomach tissue homogenate according to the principle that ADH catalyzes ethanol and NAD + to be converted into acetaldehyde and NADH.
The ALDH activity in the stomach tissue is performed by adopting an ALDH kit (Nanjing institute of bioengineering) according to the instruction. The principle is that aldehyde and NAD + are converted into acetic acid and NADH under the catalysis of ALDH, the change of a light absorption value at 340nm in a mouse stomach tissue homogenate is measured, and ALDH activity is obtained through calculation.
TNF-alpha content in stomach tissue is measured by TNF-alpha kit (Nanjing institute of bioengineering) according to the instruction.
GSH, MDA, TG and other indexes in liver tissues are also measured by adopting a corresponding kit (Nanjing institute of bioengineering), and the operation is carried out according to the instruction.
The results of the measurement of the concentration of ethanol in serum (figure 1) show that the oral administration of the probiotic composition of oligopeptide powder significantly reduces the concentration of ethanol in serum (P <0.01) compared with the model group and the protein powder group. The oral oligopeptide powder probiotic composition can promote ethanol metabolism and has the function of relieving alcoholism.
The results of the ADH and ALDH activity assays in stomach tissue (FIG. 2) showed a significant increase in both ADH and ALDH activity in stomach tissue of the oligopeptide group compared to the other groups (P < 0.01). The oral oligopeptide powder probiotic mixture can enhance the first-pass metabolism of alcohol in stomach, reduce the amount of alcohol entering blood and reduce the metabolic pressure of liver.
The measurement of TNF-alpha content in stomach tissue (FIG. 3) shows that compared with the model group, the content of TNF-alpha in stomach tissue of oligopeptide group is obviously reduced (P <0.01), which is close to that of the normal control group. The oral oligopeptide powder probiotic mixture can reduce the inflammatory reaction of alcohol on stomach tissues and has the stomach protection effect.
The determination results (figure 4) of GSH, MDA, TG and the like in liver tissues show that the GSH content of the oligopeptide group is obviously higher than that of a model group (P <0.01), the MDA content is obviously lower than that of the model group (P <0.01), and the TG content is also obviously lower than that of the model group (P <0.01), so that the oral oligopeptide powder probiotic composition can resist oxidation and reduce liver fat and has the liver protection function.
The results of this example demonstrate that oral oligopeptide powder probiotic compositions have anti-hangover, liver-protective, and stomach-protective effects.
EXAMPLE 2 ameliorating Effect of oligopeptide probiotic compositions on mice infected with helicobacter pylori (Hp)
30 male Kunming mice (male, weight range 20 +/-2 g, Nanjing Junke department biotechnology limited) with the age of 6 weeks are selected and randomly divided into 3 groups, namely a blank group, an Hp model group and an oligopeptide powder probiotic composition dry-preparation group, wherein each group comprises 10 mice. During molding, the blank group is filled with physiological saline, and each blank group is filled with 0.5 ml/d; the Hp model group and the intervention group were gavaged with Hp at 0.5 ml/d/mouse. 1 time daily for 2 weeks. After 1 week of Hp gavage, mice successfully molded are selected, the blank group and the Hp model group are gavaged by physiological saline (0.5 ml/d/mouse), the intervention group is gavaged by physiological saline containing 65mg of oligopeptide powder probiotic mixture for 10 days continuously, and the mice are sacrificed after 1 week of gavage. The serum and the stomach tissue were collected. anti-HP-IgG levels, IL-6 levels in peripheral blood of mice were determined, and ADH activity in gastric tissues was determined.
The anti-HP-IgG detection (by using H.pyrori gastric helicobacter pylori antibody detection kit, Shanghai Kai Biotechnology Co., Ltd.) results show that 30% (3/10) of mice in intervention group can not detect Hp infection, and all Hp model groups can detect Hp infection (10/10).
The result of IL-6 assay (IL-6 test kit, Nanjing institute for biological engineering) in serum (FIG. 5) indicates that IL-6 in the supernatant of Hp model group is lower than IL-6 in the supernatant of intervention group. The oral administration of the oligopeptide probiotic composition can reduce inflammatory reaction caused by Hp infection.
The result of measuring the ADH activity in the stomach tissue (figure 5) shows that Hp infection obviously reduces the ADH activity in the stomach tissue, namely the first-pass metabolism of alcohol is reduced, more alcohol enters blood after drinking, and the metabolic load of the liver is increased. However, the oral oligopeptide powder probiotic composition can improve ADH activity in Hp infected stomach tissues, promote alcohol metabolism and has the effects of protecting liver and stomach.
The results of the example show that the oral oligopeptide powder probiotic composition can reduce Hp infection or treat Hp infection, can promote first-pass metabolism of alcohol, and has a protective effect on drinking of people with Hp infection.
Example 3 Effect on changes in intestinal microbial flora in mice on Long-term alcohol consumption
40 Kunming mice (male, weight range 20 +/-2 g, Nanjing Junke Biotechnology Co., Ltd.) were randomly divided into 4 groups, namely a normal control group, a model control group, an experiment I group (oligopeptide powder group, without probiotics) and an experiment II group (oligopeptide powder probiotic composition group), and each group had 10 mice. Mice of each group were labeled, weighed and recorded prior to the experiment. The test was started after one week of acclimatization, and daily, animals of the normal control group and the model control group were gazed with 0.4ml of physiological saline, animals of the test I group were gazed with 0.4ml of physiological saline containing 55mg of oligopeptide powder (without probiotics), and animals of the test II group were gazed with 0.4ml of physiological saline containing 65mg of oligosaccharide powder probiotic mixture. After 30min, each animal in the model control group, experiment I group and experiment II group was gavaged with 56 ° Hongxing Erguotou liquor in a volume of 0.09mL/20g body weight. The experiment was carried out for 4 weeks.
After the last gastric lavage, the mice are fasted for 12h, after the water is forbidden for 1h, the mice are immediately placed on a super clean workbench after the neck is cut off, ileum contents are aseptically collected, and the mixture is uniformly mixed and placed on ice for later use. Weighing a certain amount of the ileum contents of each group of animals respectively, placing into a clean conical flask, diluting with sterile normal saline, adding 15-20 sterile glass beads, and performing shake culture at 37 ℃ for 20min to fully disperse the microorganisms. The dispersion was diluted appropriately, and 0.1mL of each dilution was applied and inoculated to a TTC nutrient agar plate, eosin methylene blue agar plate, MRS agar plate and BBL agar plate (these media were purchased from Hippobo Biotech Co., Ltd., Hippocampus, Ltd.), with 3 replicates per dilution. TTC nutrient agar medium was used to determine the total number of bacteria. Eosin methylene blue agar medium is used for coliform bacteria and faecal coliform bacteria. MRS agar medium is used for measuring the total number of lactobacillus in food. BBL agar medium is used for the isolated culture of Bifidobacterium. Escherichia coli and bacteria are cultured at 37 deg.C for 24 hr and Bacillus bifidus and lactobacillus are cultured at 37 deg.C under anaerobic condition for 24 hr. Each dilution was repeated 3 times, and the number of colonies per gram of intestinal contents was calculated and averaged.
The results in fig. 6 show that long-term drinking can reduce the number of lactic acid bacteria and bifidobacteria in the intestinal tract (P <0.01), and the oral administration of the oligopeptide powder probiotic composition can improve the intestinal microbiome of mice (compared with the model group, P <0.01), increase the content of probiotics such as lactic acid bacteria and bifidobacteria, and is superior to the simple oligopeptide group (P < 0.05).
The results of the example show that oral administration of the oligopeptide powder probiotic composition can improve beneficial flora in intestinal tract, and is helpful for restoring the balance of intestinal flora of people who drink alcohol for a long time.

Claims (10)

1. The composition for relieving alcoholism, protecting liver and protecting stomach is characterized in that every 5g of the composition comprises 1000-5000 mg of corn oligopeptide powder, 50-400 mg of wheat oligopeptide powder and 1 x 10 mg of probiotics10～10×1010Colony Forming Units (CFU).
2. The composition of claim 1, wherein said probiotic bacteria comprise lactobacillus acidophilus LA-10A, lactobacillus acidophilus NCFM, lactobacillus bulgaricus NJ441, lactobacillus rhamnosus NJ551, and bifidobacterium lactis NJ 241.
3. The composition of claim 1, wherein the corn oligopeptide flour comprises 3000-5000 mg per 5g of the composition.
4. The composition of claim 1, wherein 3000-5000 mg of corn oligopeptide powder is contained in 5g of the composition; preferably 3500 to 4500mg, more preferably 4000 mg.
5. The composition according to claim 1, wherein the wheat oligopeptide flour is 100-300 mg, preferably 150-250 mg, more preferably 200mg per 5g of the composition.
6. The composition according to claim 1, characterized in that it comprises 2 x 10 probiotics per 5g of the composition10～10×1010CFU, preferably 5X 1010～10×1010CFU, more preferably 5X 1010CFU。
7. A product or starting material for said product comprising a composition according to any one of claims 1 to 6.
8. Product according to claim 7, wherein the product is a food product, preferably a yoghurt, a lactic acid bacteria drink, a milk tablet, a solid drink or a tabletted candy.
9. The product according to claim 7, wherein the composition of any one of claims 1 to 6 is mixed, granulated or tabletted.
10. Use of a composition as claimed in any one of claims 1 to 6 or a product as claimed in claim 7 in the manufacture of a product for the prevention and/or co-treatment of chemical liver injury (e.g. alcoholic liver injury).
CN202011266653.6A 2020-11-13 2020-11-13 Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach Pending CN114468046A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011266653.6A CN114468046A (en) 2020-11-13 2020-11-13 Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011266653.6A CN114468046A (en) 2020-11-13 2020-11-13 Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach

Publications (1)

Publication Number Publication Date
CN114468046A true CN114468046A (en) 2022-05-13

Family

ID=81490930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011266653.6A Pending CN114468046A (en) 2020-11-13 2020-11-13 Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach

Country Status (1)

Country Link
CN (1) CN114468046A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115944087A (en) * 2023-01-16 2023-04-11 深圳市君恒生物科技有限公司 Probiotic composition for relieving alcoholism and protecting liver, product and application thereof
CN116019225A (en) * 2022-08-02 2023-04-28 吉林大学 Composition containing corn peptide and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108208853A (en) * 2018-01-04 2018-06-29 山东凤凰生物有限公司 A kind of relieving alcoholism and protecting liver probiotics oligopeptide compound formulation and preparation method
CN111345475A (en) * 2019-12-10 2020-06-30 营动智能技术(山东)有限公司 Composition with effects of dispelling effects of alcohol, protecting liver and repairing gastric mucosa

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108208853A (en) * 2018-01-04 2018-06-29 山东凤凰生物有限公司 A kind of relieving alcoholism and protecting liver probiotics oligopeptide compound formulation and preparation method
CN111345475A (en) * 2019-12-10 2020-06-30 营动智能技术(山东)有限公司 Composition with effects of dispelling effects of alcohol, protecting liver and repairing gastric mucosa

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116019225A (en) * 2022-08-02 2023-04-28 吉林大学 Composition containing corn peptide and application thereof
CN115944087A (en) * 2023-01-16 2023-04-11 深圳市君恒生物科技有限公司 Probiotic composition for relieving alcoholism and protecting liver, product and application thereof

Similar Documents

Publication Publication Date Title
JP5392672B2 (en) Novel lactobacilli strains and uses thereof
US11957720B2 (en) Bifidobacterium longum and functional GI disorders
TWI359668B (en)
AU2010293145B2 (en) Probiotic derived non-viable material for allergy prevention and treatment
WO2011114645A1 (en) Anti-allergic composition
CN111996153B (en) Bifidobacterium breve and application thereof
JP2016520305A (en) Association of Lactonospirae bacteria and body weight in gastrointestinal microbiota
US20210330719A1 (en) Probiotic combination for treatment of inflammatory-related gastrointestinal disorders
US20160303226A1 (en) Heat-treated formulation of bifidobacterium lactis ncc 2818 reduces allergic manifestations
CN114468046A (en) Composition with effects of dispelling effects of alcohol, protecting liver and protecting stomach
EP3897678A1 (en) Probiotic combination for treatment of allergic disorders
Mu et al. Lactobacillus plantarum KFY02 enhances the relieving effect of gardenoside on montmorillonite induced constipation in mice
JP5531283B2 (en) Intestinal immunity regulator
HoSoNo et al. Impact of fermented milk on human health: cholesterol‐lowering and immunomodulatory properties of fermented milk
JP2007055986A (en) Antiallergic agent
JPWO2018003898A1 (en) Composition for promoting cartilage regeneration
JP2010132580A (en) Lactobacillus having lipid metabolism-ameliorative effect
AU742479B2 (en) Compositions and methods for human gastrointestinal health
WO2005094848A1 (en) Agent for preventing or suppressing hepatopathy and functional food for preventing or suppressing hepatopathy
Botes Survival of probiotic lactic acid bacteria in the intestinal tract, their adhesion to epithelial cells and their ability to compete with pathogenic microorganisms
Prajapati et al. Probiotics and health claims: an Indian perspective
Rao et al. Probiotics and Diet for Chronic Diseases Prevention
Ngwenya Influence of probiotics on canine health

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination